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Abstract
The human trabecular meshwork (TM) expresses many genes that have been associated with
physiological (bone, cartilage, teeth) and pathological (vascular systems, kidney) calcification. In
particular, the TM highly expresses the inhibitor of calcification Matrix Gla (MGP) gene, which
encodes a vitamin K-dependent protein that requires post-translational activation to inhibit the
formation of calcium precipitates. TM cells have high activity of the activating γ-carboxylase enzyme
and produce active MGP. Silencing MGP increases the activity of alkaline phosphatase (ALP), an
enzyme of the matrix vesicles and marker of calcification. Overexpressing MGP reduces the ALP
activity induced by bone morphogenetic 2 (BMP2), a potent inducer of calcification. In this review
we gathered evidence for the existence of a mineralization process in the TM. We selected twenty
regulatory calcification genes, reviewed their functions in their original tissues and looked at their
relative abundance in the TM by heat maps derived from existing microarrays. Although results are
not yet fully conclusive and more experiments are needed, examining TM expression in the light of
the calcification literature brings up many similarities. One such parallel is the role of mechanical
forces in bone induction and the high levels of mineralization inhibitors found in the constantly
mechanically stressed TM. During the next few years, examination of other calcification-related
regulatory genes and pathways, as well as morphological examination of knockout animals would
help elucidate the relevance of a calcification process to TM overall function.
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1. Introduction
The trabecular meshwork (TM) is a soft spongiform tissue whose primary function is that of
maintaining a physiological resistance to the flow of aqueous humor. Failure to regulate such
resistance results in an elevation of intraocular pressure (IOP), the major risk factor for the
development of glaucoma (Kass et al., 2002). The TM has also a very unique architecture. It
contains cells, beams and fibrils, open extracellular spaces and extracellular material, all
arranged in a characteristic flexible layer-like structure. Maintenance of the softness nature of
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such structure is of highest relevance to the TM’s function. For that, the TM needs to have in
place molecular mechanisms that would maintain the physical properties of elasticity, tension
and softness.
The aqueous humor flows continuously in the anterior chamber and exits the eye wandering
in between the TM’s cells and extracellular matrix (ECM). Because of this continuous flow,
the TM is the target of numerous biochemical and mechanical factors, which in turn trigger
differential expression of its genes. The TM transcriptome is quite diverse and reflects the
variety of mechanisms used by the tissue to counteract insults and ensure a physiological
outflow facility. Genes expressed in the TM reveal that secretion, cell-matrix interactions,
cytoskeletal reorganization and especially, ECM functions are key for its proper operation.
Expression of genes that affect ECM properties, in particular those affecting calcification in
other tissues has been observed in the TM (Borrás, 2008a; Borrás, 2008b; Gonzalez et al.,
1999; Gonzalez et al., 2000; Vittitow and Borrás, 2004). The most striking similarity is the
presence of the gene encoding the inhibitor of calcification Matrix Gla (MGP) which was
shown to be one of the highest expressed genes in the tissue (Borrás, 2008a). The fact that
MGP has been confirmed as an inhibitor of calcification (Proudfoot and Shanahan, 2006) and
that overexpression and silencing of this gene in the TM results in alterations of calcification
markers (Xue et al., 2006; Xue et al., 2007) is a strong indication that biomineralization
processes might be ongoing in this tissue and need to be counteracted.
Mineralization is the result of the formation of a calcium-phosphate precipitate (hydroxyapatite
crystal). Formation of the first hydroxyapatite crystal takes place in matrix vesicles which are
generated in the plasma membrane of the cells and released upon uploading calcium and Pi
(Anderson, 2003). The matrix vesicles contain alkaline phosphatase (ALP) activity which
produces a local increase of free phosphate and results into the formation of the apatite crystal
(Ali et al., 1970). In the ECM, the matrix vesicle releases the crystal to the extracellular
compartment where it gets deposited on collagen fibrils and continues to grow by a
thermodynamic process using the first hydroxyapatite crystal as a template (Anderson, 2003;
Yang et al., 2004).
Contrary to the original belief that calcification was due to spontaneous precipitation of
hydroxyapatite, it is now known that mineralization is a highly regulated process (Steitz et al.,
2001). Physiological precipitation of calcium-phosphate crystals occur in the ECM of bone,
cartilage and teeth. The mineralization process is controlled by local cells via the secretion of
mineral-binding ECM proteins and proteoglycans, the transport of inorganic phosphate to the
extracellular compartment, and by enzymes of the alkaline phosphatase family, which can also
degrade mineralization inhibitors (Addison et al., 2007; Giachelli, 2005).
Calcification of soft tissues occurs during pathological conditions and has important clinical
implications. Ectopic calcifications are well known to occur in cardiovascular diseases,
artherosclerosis, arthritis, end-stage kidney disease and cancers. The molecular mechanisms
governing ectopic calcification are pretty similar to those regulating physiological
calcification, and mineral formation in the soft tissues depends on a balance of “procalcific”
and “anticalcific” regulatory molecules (Giachelli, 2005). Very recently it has also been shown
that in addition to the mineralization occurring in the ECM, calcium-phosphate mineral
deposits can occur intracellularly (Azari et al., 2008). Such deposits have been observed in
electron-dense vesicular structures in Purkinje cells during cerebellum calcification (Ando et
al., 2004).
There is extensive evidence that vascular smooth muscle cells (VSMC), which originate from
pluripotent mesenchymal cells, transdifferentiate into chondrocytes and undergo chondrogenic
commitment leading to vascular calcification. TM cells derived from the mesenchymal cells
Borrás and Comes Page 2













of the neural crest and exhibit many of the characteristics of VSMCs (Lütjen-Drecoll and
Rohen, 1996). Since they contain key calcification markers, it has been proposed that TM cells
under certain conditions, could undergo the same fate (Xue et al., 2006; Xue et al., 2007).
In this article we review the current evidence of the presence of calcification in the TM with
a particular focus in the presence and relative abundance of calcific and anticalcific regulatory
proteins (Figure 1a and b). We review the function that these mineralization associated genes
play in physiological calcification and in ectopic, pathological mineralization in their
established tissues and discuss the meaning of their presence or absence in the TM.
2. Alkaline phosphatase (ALP)
ALP is an enzyme that hydrolyzes a variety of substrates that lead to increases of Pi. It is an
essential component of matrix vesicles where it leads to increased orthophosphates required
for the growing hydroxyapatite crystal. ALP is activated when a pluripotent mesenchymal cell
commits to differentiate into a bone-forming cell (osteoblast) and it is significantly elevated
in matured committed osteoblasts (Hashimoto et al., 1998; Pittenger et al., 1999). ALP also
allows inactivation of mineralization inhibitors (Magne et al., 2005). The disease
hypophosphatasia, characterized by defective bone mineralization, is linked to a mutation in
the ALP gene (Mornet, 2000). ALP is a well established early marker of osteogenesis
(Hashimoto et al., 1998; Luo et al., 2004) and vascular calcification (Jono et al., 2000a;
Shanahan et al., 2000; Tanimura et al., 1986). Under normal conditions, ALP is not expressed
in the TM (Figure 1a and b). However, ALP activity was reported increased in HTM cells aged
in culture (Xue et al., 2006) and after treatment with DEX, TGFβ2 and MGP siRNA (Xue et
al., 2007). ALP activity was also significantly higher in the intact TM tissues from
glaucomatous patients (Xue et al., 2007).
3. Osteocalcin (BGLAP/BGP)
Also known as Bone Gla protein, osteocalcin is expressed in osteoblasts and in osteoblast-like
calcifying vascular cells. Osteocalcin is highly expressed during the last stages of bone
formation and is a characteristic component of the bone matrix of differentiated osteoblasts.
Osteocalcin is highly induced by vitamin D3 (Viereck et al., 2002), a potent differentiation
factor for osteoblasts (Owen et al., 1991), and considered essential for the calcification of the
bone matrix. However, the involvement of osteocalcin in mineralization is complex.
Osteocalcin null mice have increased bone density (Ducy et al., 1996) indicating that
osteocalcin functions to suppress excess calcification without affecting initial mineralization.
Although osteocalcin has not been reported as induced in the TM (Borrás, 2003; Rozsa et al.,
2006; Vittal et al., 2005; Zhao et al., 2004), it appears expressed at low levels in microarrays
of normal cells and tissues (Figure 1A and 1B).
4. Biglycan (BGN)
Biglycan (alias dermatan sulfate proteoglycan) forms part of the small leucine-rich repeat
family of proteoglycans (SLRPs), which are associated with the commitment to the osteogenic
phenotype in osteoblast differentiation (Balint et al., 2003). It binds to collagen type I
(Schonherr et al., 1995) and TGFβ (Hildebrand et al., 1994) and is present in atherosclerotic
plaques associated with collagen type I and III. Disruption of the biglycan gene in mice leads
to an osteoporosis-like phenotype with reduced bone strength (Xu et al., 1998), while its
upregulation is associated with osteoarthritis progression in mice (Watters et al., 2007).
Biglycan is closely related to Fibromodulin and Decorin. Together with elastic and collagen
fibers, dermatan sulfate proteoglycans form part of the core of the TM beams (Lütjen-Drecoll
and Rohen, 1996). In the TM, biglycan is moderately expressed (Figure 1a and b) and it is
altered by mechanosensitive insults of pressure and stretch (Borrás, 2008a)
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5. Bone morphogenetic protein 2 (BMP2)
BMP2 belongs to the superfamily of TGFβ proteins. Of all the BMPs, only BMP2 and BMP4
have been shown to induce osteoblast differentiation. BMP2 by itself has the full potential to
initiate bone formation and to induce the differentiation of multipotent mesenchymal
progenitor cell lines to the osteogenic lineage (Ducy and Karsenty, 2000; Riley et al., 1996).
Osteogenesis signaling of BMP2 involves the SMAD proteins and a number osteoblast-specific
transcription factors such as Hoxc-8, RUNX2 and osterix (Matsubara et al., 2008; Viereck et
al., 2002; Yang et al., 2000). BMP2-induced osteogenesis is known to require activation of the
canonical Wnt signaling pathway (Rawadi et al., 2003; Vaes et al., 2005), which plays a key
role in the regulation on bone remodeling (Goldring and Goldring, 2007). As well, BMP2
induces osteogenesis-like characteristics in primary human TM (HTM) cells (Xue et al.,
2006). Overexpression of BMP2 induces ALP activity in primary HTM cells and its encoded
protein colocalizes with the calcification inhibitor Matrix Gla (MGP) (Xue et al., 2006).
However, BMP2 expression was reported downregulated in HTM DEX-treated cells (Rozsa
et al., 2006). BMP2 osteogenic action can be inhibited by its binding to MGP in various cell
types, including the TM (Boström et al., 2001; Wallin et al., 2000; Xue et al., 2006).
6. Cadherin 11 (CDH11)
Also known as Osteoblast Cadherin, cadherin 11 is a calcium-dependent cell-cell adhesion
protein which is highly expressed in osteoblasts. It was originally isolated as a protein expressed
specifically in osteoblasts (Okazaki et al., 1994) and then found to be critical for BMP2 induced
osteogenic differentiation (Cheng et al., 1998). Cadherin 11 directly regulates the
differentiation of mesenchymal cells into the cells of the osteo- and chondro-lineages (Kii et
al., 2004). Cadherin knockout mice exhibit reduced bone density (Kawaguchi et al., 2001).
Cadherin 11 is quite abundant in the TM (Borrás, 2003; Tomarev et al., 2003) and is upregulated
in primary HTM cells versus intact tissue (Figure 1a and b).
7. Collagen type I (COL1A1)
Collagen type I is an integral component of calcified matrix vesicles (Glimcher, 1990; Katz
and Li, 1973; Yang et al., 2004) and the type I collagen fibril plays a critical role in bone
mineralization. The mineral in bone is located primarily within the fibril; during mineralization
the collagen fibril is formed first and then water within the fibril is replaced with mineral. In
ectopic calcification, VSMCs cultured on collagen type I enhance calcification (Watson et al.,
1998). Mutations in collagen type I are associated with osteogenesis imperfecta (Kuivaniemi
et al., 1997). In the TM, collagen type I is an important structural component of the ECM and
constitutes part of the core of the TM beams (Lütjen-Drecoll and Rohen, 1996). Collagen type
I is the substrate of matrix metallopeptidase 1 (MMP1), a regulator of outflow facility (Bradley
et al., 1998), and it is induced by ascorbic acid (Zhou et al., 1998), a potent inducer of
calcification. Collagen type I mRNA is induced in primary HTM cells versus perfused intact
tissue (Figure 1a and b).
8. Connective Tissue Growth Factor (CTGF)
CTGF plays a major role in angiogenesis, chondrogenesis, osteogenesis, tissue repair, cancer
and fibrosis (Shi-Wen et al., 2008). Mice deficient in CTGF die soon after birth because of
their inability of their rib cage to ossify properly (Ivkovic et al., 2003). In vitro, treatment of
primary osteoblast cultures with recombinant CTGF (rCTGF) causes an increase in cell
proliferation, ALP activity and calcium deposition (Safadi et al., 2003). In vivo, CTGF
promotes endochondral ossification and regeneration of damaged cartilage (Kikuchi et al.,
2008). Application of the CTGF in a gelatin hydrogel base to a rat femur resulted in induction
of osteoblastic mineralization within 2 weeks. Delivery of rCTGF into the femoral marrow
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cavity of rats induced osteogenesis (Safadi et al., 2003). CTGF was also shown to be
upregulated during fracture healing in a mouse model (Kikuchi et al., 2008). This gene is highly
abundant in the TM (Tomarev et al., 2003), is elevated in the aqueous humor of patients with
pseudoexfoliation glaucoma (Ho et al., 2005), and shows significant induction in microarrays
of samples subjected to mechanical stress and DEX (Rozsa et al., 2006; Vittal et al., 2005).
9. Decorin (DCN)
Decorin is another member of the SLPRs and contains both chondroitin and dermatan sulfate
glycosaminoglycans. It is highly expressed in bone cells and co-localizes to the mineralized
ECM of bones (Waddington et al., 2003). Decorin co-localizes with collagen, aids in the
assembly of collagen fibers and regulates hydroxyapatite crystal growth (Azari et al., 2008;
Boskey et al., 1997; Giachelli, 1999). Mice lacking both decorin and biglycan exhibit an
osteoporetic phenotype (Corsi et al., 2002). Decorin also induces calcification of arterial
smooth muscle cell cultures and co-localizes to mineral deposition in human atherosclerotic
plaque (Fischer et al., 2004). Decorin was recently reported to play a role in intracellular
pathological calcification of soft tissues (Azari et al., 2008). Decorin is highly abundant in the
TM (Gonzalez et al., 2000; Tomarev et al., 2003) and one of the most abundant of all
calcification related genes selected for this review (Figure 1a and b). Decorin is one of the main
proteoglycans of the matrix of the TM (Borrás, 2003; Ueda et al., 2002). Its mRNA was reported
both up- and downregulated in the HTM cells after DEX (Borrás, 2008a; Ishibashi et al.,
2002; Rozsa et al., 2006).
10. Fibromodulin (FMOD)
Fibromodulin is an ECM keratan sulfate proteoglycan and another member of the SLPRs. It
interacts with collagen type I fibrils and has been shown to regulate collagen fibrillogenesis
(Ameye and Young, 2002). Fibromodulin binds to collagen type I at the same site of lumican
which is a different binding site than that of the decorin (Svensson et al., 2000). It also binds
to TGFβ (Hildebrand et al., 1994). The binding of fibromodulin to collagen impairs the fibril
growth and creates thinner collagen fibrils (Font et al., 1998). Mice deficient in fibromodulin
have weak tendons and ligaments causing osteoarthritis (Ameye and Young, 2002; Svensson
et al., 1999). The expression of this SLRP in the TM is moderate (Figure 1a and b), but it is
significantly upregulated by mechanical stimuli (Borrás, 2008a; Vittal et al., 2005).
11. Bone Sialoprotein (IBSP)
Bone Sialoprotein or Integrin-binding Sialoprotein, is an extracellular glycoprotein
synthesized by osteoblasts and osteoclasts (Bianco et al., 1991; Fisher et al., 1983). It is a major
noncollagenous, structural protein of the bone matrix and other mineralizing connective tissues
(Chen et al., 1992). Studies on rat development showed that it has a specific role in the initial
stages of connective tissue mineralization (Chen et al., 1992). Bone sialoprotein binds to
collagen (Fujisawa et al., 1995) and it also has an RGD (Arg-Gly-Asp) domain (Oldberg et al.,
1988). IBSP was reported to be one of the Wnt pathway proteins to be significantly
downregulated in an array analysis of osteoarthritic bone (Hopwood et al., 2007). To date this
protein does not appear to be very relevant for the TM. It is not (or barely) expressed (Figure
1a and b) and there are not reports about its induction in the tissue.
12. Matrix Gla (MGP)
Matrix Gla (MGP) is a vitamin K-dependent protein found most abundantly in bone and
cartilage. MGP is activated post-translationally by conversion of its glutamic acid residues to
γ-carboxylglutamic (Gla) by the enzyme γ-carboxylase (Price et al., 1983). Once activated,
MGP regulates calcium deposition by binding to calcium and calcium crystals, inhibiting
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BMP2 and binding to ECM components, such as elastin and vitronectin (Proudfoot and
Shanahan, 2006). MGP was initially discovered in demineralized extracts of bone matrix (Price
and Williamson, 1985) but it is highly expressed also in VSMCs (Shanahan et al., 1993). MGP
knockout mice develop extensive calcification of elastic arteries and cartilage, and die at two
months due to blood-vessel rupture (Luo et al., 1997). Today it is well established that the
protection of soft tissue calcification is partly because of the complex of calcium to inhibitors
of calcification, such as MGP (Proudfoot and Shanahan, 2006).
MGP is one of the most expressed genes in the human TM tissue (Borrás, 2008a; Gonzalez et
al., 2000; Tomarev et al., 2003) and its expression is affected by insults associated with
glaucoma such elevated pressure (Vittitow and Borrás, 2004) and mechanical stretch (Vittal
et al., 2005). Cells of the TM have also been shown to have high carboxylase activity and to
produce active MGP (Xue et al., 2006). Expression of MGP and γ-carboxylase activity is
decreased in HTM cells aged in culture (Xue et al., 2006) and in glaucomatous TMs where the
ALP activity marker is significantly increased (Xue et al., 2007). Overexpression of MGP
reduces ALP activity in a model of BMP2-induced osteogenesis (Xue et al., 2006) while
silencing of MGP increases ALP activity (Xue et al., 2007). In humans, a rare inherited disease,
Keutel syndrome (Munroe et al., 1999; Teebi et al., 1998), characterized by abnormal
calcification of cartilage and stenosis of pulmonary arteries has been linked to a defective MGP
gene. Ophthalmological evaluation in several patients described decreased vision and optic
nerve atrophy (Hur et al., 2005; Teebi et al., 1998). However, a comprehensive TM and IOP
study in Keutel patients is lacking, in part because to date only about 20 cases have been
reported worldwide (Hur et al., 2005)
13. Osteoglycin (OGN)
Osteoglycin, also known as Mimecan and Osteoinductive Factor, is another extracellular
protein member of the SLPRS family of proteoglycans, and thus associated with the
commitment to the osteogenic phenotype in osteoblast differentiation (Balint et al., 2003).
Osteoglycin shares about 30% homology with decorin and biglycan. It is highly expressed in
osteoblasts, calcifying vascular cells and cornea (Balint et al., 2003; Shanahan et al., 1997;
Tasheva et al., 2002). Recently it was shown also to be highly expressed in the cochlea
(Williamson et al., 2008). Mice lacking osteoglycin show an increase in bone density (Ducy
et al., 1996) as well as in collagen fibril diameter, suggesting a role in fibrillogenesis (Tasheva
et al., 2002). Osteglycin was identified in atherosclerotic plaques (Fernandez et al., 2003).
Implantation of osteoglycin plus TGFβ type 1 or 2 into subcutaneous tissues of rats induces
ectopic formation of bone at the implantation site (Kukita et al., 1990). Osteoglycin expression
is altered by mechanical insults in a variety of tissues, including the TM (Borrás, 2008a; Patel
et al., 2007b; Wong et al., 2003). A proteomic analysis has identified the presence of this gene
in normal and glaucomatous TM tissues (Bhattacharya et al., 2005) while a differential
expression microarray found osteoglycin upregulated in tissues from primary open angle
glaucoma patients (Diskin et al., 2006).
14. Osteomodulin (OMD)
Osteomodulin, also named Osteoadherin, is a keratan sulfate proteoglycan that belongs to the
SLRP’s family (Sommarin et al., 1998). It was found expressed in bovine mature osteoblasts
and in odontoblasts, leading to the suggestion that it may be implicated in bone mineralization
(Buchaille et al., 2000). By microarray analysis, osteomodulin was found to be associated with
BMP2-induced differentiation of premyoblasts to the osteogenic lineage (Balint et al., 2003).
Moreover, in vitro overexpression of osteomodulin in osteoblasts resulted in increased ALP
activity and mineralization while silencing it by siRNA reduced the calcification process (Rehn
et al., 2008). Recently osteomodulin has been proposed as an osteoblast differentiation marker
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which is induced by osteoclast activity (Ninomiya et al., 2007). Osteomodulin has been
identified as a mechanosensitive gene in osteoblasts (Patel et al., 2007b) and in the TM
(Vittitow and Borrás, 2004).
15. Osteoclast stimulating factor (OSTF1)
Osteoclast-stimulating factor 1 is an intracellular protein produced by osteoclasts to enhance
osteoclast activity and bone resorption (destruction) (Reddy et al., 1998). The stimulatory
osteoclast activity is exerted through the binding of the osteoclast specific factor to other
proteins. Binding of OSTF1 to survival motor neuron gene product (SMN) induces secretion
of soluble osteoclast stimulators (Shanmugarajan et al., 2007). Mutations in SMN result in
spinal muscular atrophy, a children’s disease which involved motor neuron dysfunction and
congenital bone fractures (Shanmugarajan et al., 2007). This gene is present but expressed at
low levels in the TM (Figure 1a and b) and there are not reports on its induction.
16. Periostin (POSTN)
Periostin, also known as Osteoblast-specific Factor 2 (OSF2), is a secreted protein by
osteoblasts (Horiuchi et al., 1999). Periostin is expressed in collagen rich tissues that are
subjected to constant mechanical stresses. It is required to mediate and cushion mechanical
forces exerted during mastication in teeth (Rios et al., 2005). Periostin-deficient mice have
skeletal defects (Rios et al., 2005) and have revealed that periostin can regulate collagen type
I fibrillogenesis and viscoeslastic properties of connective tissue (Norris et al., 2007). Recently,
periostin was found to be a new member of the vitamin K-dependent, γ-carboxylated proteins.
It was localized to bone nodules in bone marrow-derived mesenchymal stromal cells and
suggested to have a role in mineralization (Coutu et al., 2008). Microarray studies in the human
TM showed that periostin expression was increased in perfused organ cultures by elevated
pressure (Vittitow and Borrás, 2004), and in cultured TM cells by mechanical stretch (Vittal
et al., 2005) and TGFβ (Vittal et al., 2005; Zhao et al., 2004).
17. Parathyroid hormone-like hormone (PTHLH)
Parathyroid hormone-like hormone, a secreted peptide also known as Parathyroid hormone-
related protein (PTHrP), is involved in calcium and phosphate homeostasis. It was discovered
as a humoral factor implicated in the cause of hypercalcemia in lung malignancy (Suva et al.,
1987). It is a local regulator of calcification and addition of the exogenous peptide to VSMCs
inhibits ALP and calcification (Jono et al., 1997). PTHLH is downregulated by vitamin D3
(Jono et al., 1998; Okazaki et al., 2003), a physiological mediator of bone formation (Chapuy
et al., 1992), through an interaction of the vitamin D receptor with a promoter negative element
in PHTLH. PTHLH is thus considered an inhibitor of calcification (Okazaki et al., 2003). In
the TM, PTHLH is moderately expressed (Figure 1a and b) and it was reported as
downregulated by DEX in primary HTM cells (Rozsa et al., 2006). Curiously, in primary HTM
cells, PTHLH is increased after overexpression of wild-type TIGR/MYOC while it is
downregulated after overexpression of the Q368STOP mutant (our laboratory, unpublished).
18. Osteoblast specific factor 2 (RUNX2)
Osteoblast-specific Transcription Factor 2, also known as Core-binding Factor α1 (Cbfa1), is
a member of RUNX family of transcription factors (Ducy et al., 1997). It was isolated as the
factor binding to an osteoblast-specific promoter element in osteocalcin (Ducy et al., 1997)
and then found to regulate the expression of key osteoblast specific genes (Ducy et al., 1997).
ALP, osteocalcin and osteopontin contain Runx2/Cbfa1 binding sites. First believed to be
expressed only in cells of osteogenic lineage, RUNX2/Cbfa1 is induced when VSMCs gain an
osteogenic phenotype and lose their lineage markers smooth muscle 22α and smooth muscle
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α-actin (Steitz et al., 2001). This transcription factor is moderately expressed in the TM (Figure
1A and 1B) and there are no reports of its induction.
19. Osteonectin (SPARC)
Osteonectin, also called SPARC (Secreted Protein Acidic and Rich in Cysteine) and BM-40
(Basement membrane 40), is a calcium and collagen binding ECM glycoprotein (Lane and
Sage, 1994). It was first identified as highly abundant in mineralized tissues (Termine et al.,
1981). Subsequent studies showed that osteonectin also belongs to a group of regulatory ECM
molecules known as matricellular proteins, which modulate cell-matrix interactions but do not
have a structural role in the matrix (Bornstein and Sage, 2002). Osteonectin is expressed at
sites of active skeleton and ECM remodeling (Lane and Sage, 1994). Null mice have decreased
osteoblast and osteoclast formation resulting in decreased bone density (Delany et al., 2000).
As a matricelullar protein, osteonectin contains modular domains that can function
independently to bind cells and ECM and consequently, it has been shown to have multiple
biological activities. Recently, it has been proposed to be a collagen chaperone, enhancing
collagen stability intracellularly and regulating collagen fibrillogenesis extracellularly
(Martinek et al., 2007). SPARC is very abundant in the TM (Figure 1A and 1B) where it has
been shown to be a mechanosensitive gene that responds to elevated pressure and stretch
(Borrás, 2008a; Vittal et al., 2005).
20. Osteopontin (SPP1)
Osteopontin, also known as Secreted Phosphoprotein 1, is a noncollagenous phosphoprotein
associated with biomineralization in bone tissue as well as with ectopic calcification (Jono et
al., 2000b). Osteopontin binds tightly to hydroxyapatite and inhibits hydroxyapatite crystal
growth and calcification in vivo and in vitro (Steitz et al., 2002). Experiments using a mouse
model of subcutaneous implants of biopsy punches of aortic valves showed that osteopontin
is a natural inhibitor of ectopic calcification in vivo where not only inhibits mineral deposition
but also actively promotes its dissolution (Giachelli, 2005; Steitz et al., 2002). Osteopontin
also has a multidomain structure and functions as a matricellular protein (Giachelli and Steitz,
2000); it binds to cell receptors through an integrin-binding site (RGD) as well as to
extracellular proteins.
Experiments in osteopontin-deficient mice showed that osteopontin is not involved in normal
bone development but is important in bone remodeling by influencing the resorption of bone
by osteoclasts (Franzen et al., 2008). After reduction of mechanical stress, osteopontin
knockout mice reverted the bone loss displayed by the wild-type due in part to a deficit in bone
resorption (Ishijima et al., 2001). Osteopontin is highly expressed in human TM tissue
(Gonzalez et al., 2000; Tomarev et al., 2003) and is downregulated in HTM cells in culture
(Gonzalez et al., 1999) (Figure 1A and 1B).
21. Osteoprotegerin (TNFRSF11B)
Osteoprotegerin is a member of the Tumor Necrosis Factor receptor gene superfamily.
Osteoprotegerin is secreted by osteoblasts and binds specifically to Osteoprotegerin Ligand,
an osteoclast differentiation factor also known as RANKL (receptor activator of NFκB).
Binding of the two proteins inactivates the ligand, which is an essential factor for osteoclast
development (Theoleyre et al., 2004). Thus, osteoprotegerin regulates bone remodeling by
decreasing osteoclast, bone destruction activity and increasing bone strength. Mice deficient
in OPG-L, or that overexpress OPG, lack osteoclast activity and develop severe osteopetrosis
(increased bone density) (Kong et al., 1999; Simonet et al., 1997). In contrast, mice lacking
OPG develop osteoperosis and show high rate of pathological fractures and arterial
calcification (Bucay et al., 1998). Recently Osteoprotegerin has been shown to inhibit
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apoptosis-induced by TRAIL (TNF-related apoptosis inducer ligand) (Holen and Shipman,
2006) and to be regulated by the Wnt/βcatenin pathway (De Toni et al., 2008). Osteoprotegerin
is moderately expressed in the TM and it is significantly downregulated by DEX (Rozsa et al.,
2006).
22. Calcium deposition and ALP activity in the trabecular meshwork
In order to assess the presence of a calcification process in the TM calcification, studies in
HTM cells and intact perfused tissue have been conducted under different aging and
glaucomatous conditions using chemical, biological and histological calcification assays. Xue
et al. (2006) reported that primary HTM cells aged in cultured for four weeks had higher levels
of calcium, increased ALP activity and formed calcification nodules which stained with alizarin
red (Xue et al., 2006) (Figure 2). The authors also reported that treatment with DEX likewise
resulted in elevated cellular calcium concentration, increased ALP activity and the appearance
of calcification nodules (Xue et al., 2007) (Figure 3). In a similar study, perfused TM tissue
from glaucoma donors showed higher ALP activity than aged-matched controls while the
mRNA expression of MGP and its activation enzyme, γ-carboxylase was reduced (Xue et al.,
2007). Treatment with TGFβ2 induced the activity of the calcification marker ALP and reduced
the expression of the inhibitor MGP, and silencing MGP resulted also in an increased of activity
of the ALP enzyme (Xue et al., 2007).
Taken together these studies are very suggestive but not yet determinative. Although evaluation
of ALP is the most widely used calcification marker in the physiological (bone) and
pathological (vascular calcification) fields, other proteins involved in the regulation of
biomineralization (such osteocalcin, osteopontin, decorin, biglycan etc) would need to be
tested. Although calcium deposition experiments are very encouraging, a greater number needs
to be performed. As well, morphological examination of the TM of the knockout mice for the
key bone associated genes would be very informative.
23. Concluding remarks
Our intent in writing this review was not only to report on the calcification studies done in the
TM, but to expose the eye community to the vast literature of physiological and pathological
calcification. At the gene level, the similarities with the TM are at times staggering (Figure 1A
and B). Definitely more studies are needed, but the evidence so far suggests that calcification,
or its prevention, might be a very important processing for the TM. Nature does not waste its
own resources and a cell would not be expending its transcription machinery in abundantly
transcribing a gene (like MGP) whose function would not be used. Further, as we learn by the
calcification literature, mechanical stimuli such as tension or pressure are key to building
stronger bones and teeth (Patel et al., 2007a; Wong et al., 2003). It would make sense that a
soft tissue like the TM, which is continually subjected to mechanical pressure, would need to
protect itself from such happening. Nonetheless, quite a few issues need to concur and be
resolved. It is for instance curious that, even if it has not been specifically addressed, none of
the extensive electron microscopy studies available has ever reported on the presence or
absence of calcification in the electron dense structures of the human trabecular meshwork.
Also, although MGP conserves the inhibition of calcification role in the TM (Xue et al.,
2006), the function of additional osteogenic genes in the outflow tissue is not yet known. As
many of the genes described here, such as biglycan, SPARC or fibromodulin, have other
functions than calcification, their main functional role in the TM could be different and no
calcification related. Experiments like those conducted with MGP, would need to be
performed. In conclusion, maintaining TM’s ECM softness by preventing calcification might
be an important mechanism to influence outflow facility. Such a mechanism could be an active
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part of the homeostasis processes that tend to adjust the elevated pressure insult and therefore,
the development of glaucoma.
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Figure 1. Heat map of twenty calcification regulatory genes in the human TM
Human U133Plus2.0 Affymetrix Genechips analyzed with the GeneSpring software package.
Expression signals in each chip are compared to a median value. Change from the median is
visually represented by a color assignment (scale at right). The custom calcification gene list
was generated from the Gene Ontology lists on Gene Spring. A: human TMs from perfused
post-mortem eyes used as control in several experiments. Ages of donors were between 62–
92 years old (all Caucasians and all but one males). Perfusion was conducted at constant flow
for 3 to 6 days under standard, serum free conditions. Chips 112 – 113 were untreated; chips
116–129 were treated with a control recombinant adenovirus carrying no gene (AdNull). B:
primary HTM cells from control cultures. Primary cells were all from the same line (donor 43
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year old Caucasian male), at passage 4 and grown on 10% FBS. Each chip’s RNA originated
from an independent experiment. Chips 13–15 were untreated; chips 17–23 were treated with
a control recombinant adenovirus carrying no gene (AdNull).
Borrás and Comes Page 19













Figure 2. Evidence of calcification in aged HTM cells in cultures
Measurements of normalized calcium content (top) and alkaline phosphatase activity (middle)
in young (1 week in culture) and old (4 weeks in culture) primary HTM cells at passage 6.
Bottom panel shows alizarin red staining of calcification nodules on cells aged in culture for
12 weeks (Xue et al., 2006).
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Figure 3. Evidence of calcification in HTM cells treated with Dexamethasone (DEX)
Measurements of normalized calcium content (top, 10 days post-treatment) and alkaline
phosphatase activity (middle) in untreated and DEX-treated (0.1µM) primary HTM cells.
Bottom panel shows alizarin red staining of calcification nodules on DEX-treated cells for 4
days. (Xue et al., 2007 and unpublished).
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